CN101590103A - A kind of leukemic Chinese medicine composition and preparation method thereof that is used for the treatment of - Google Patents
A kind of leukemic Chinese medicine composition and preparation method thereof that is used for the treatment of Download PDFInfo
- Publication number
- CN101590103A CN101590103A CNA2008101132197A CN200810113219A CN101590103A CN 101590103 A CN101590103 A CN 101590103A CN A2008101132197 A CNA2008101132197 A CN A2008101132197A CN 200810113219 A CN200810113219 A CN 200810113219A CN 101590103 A CN101590103 A CN 101590103A
- Authority
- CN
- China
- Prior art keywords
- radix salviae
- salviae miltiorrhizae
- preparation
- chinese medicine
- realgar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses leukemic Chinese medicine composition of a kind of treatment and preparation method thereof.This Chinese medicine composition is to be prepared from according to a certain weight ratio by Realgar, Indigo Naturalis, Radix Salviae Miltiorrhizae, Borneolum Syntheticum.It can be prepared to any common drug dosage form.The effect that Chinese medicine composition of the present invention has heat clearing away, detoxifies, invigorates blood circulation is used for the treatment of various acute and chronic leukemias.
Description
Technical field
The present invention relates to a kind of leukemic Chinese medicine composition and preparation method thereof that is used for the treatment of, belong to the field of Chinese medicines.
Background technology
Leukemia is the malignant disease of hemopoietic tissue.Be characterized in that unrestrictedly hypertrophy of a large amount of leukaemias is arranged in bone marrow and other hemopoietic tissue, and enter peripheral blood, and the manufacturing of normal plasma cell is obviously suppressed, this disease occupies the first place in the youngster malignant disease, the cause of disease still imperfectly understands so far, virus may be main virulence factor, may be morbific cofactor but also have many factors as radiation, chemical toxicant (benzene etc.) or medicine, heredodiathesis etc.According to jejune degree of leukaemia and leukemic natural history, be divided into acute and chronic two big classes.According to the proliferative cell type, can be divided into granulocytic, lymphatic and monocarpotic cellularity three classes.Mainly show as infection, heating, anemia and hemorrhage.
Main treatment has following a few class chemotherapy, radiotherapy, target therapy.Part high risk patient need carry out bone marrow transplantation.Over nearly 10 years, along with the progress of molecular biology, biogenetics, more deep to leukemic cause of disease epilepsy reason understanding, new therapy, the discovery of novel drugs and the use of Chinese medicine are taken on a new look leukemic prognosis greatly simultaneously.
Chinese medicine does not have " leukemia " this name of disease, according to its clinical manifestation such as heating, anemia, hemorrhage, liver spleen and lymphadenectasis etc., be attributable to the traditional Chinese medical science " asthenia ", category such as " acute pulmonary tuberculosis ", " hot labor ", " blood disorder ", " sucutaneous nodule ".Though do not have unified dialectical foundation, the general trend of traditional Chinese medical science leukemia differentiation of symptoms and signs for classification of syndrome is still based on type of deficiency of both QI and YIN, QIXUELIANGXU type, pyretic toxicity stagnation type and blood stasis accumulation type.
The inventor thinks that the leukemic cause of disease is caused by " malicious heresy is gone into blood ", and this evil poison enters versatile thermal burn the moon behind the body, thereby again this malicious heresy is called burning hot heresy, also is referred to as fire-toxin, pyretic toxicity.In addition, evil poison also should comprise the endogenous toxin due to the internal injury.The internal organs meridians of evil poison invasion human body under certain endogenous cause of ill condition, from outward appearance to inner essence, or poison is from interior and give birth to, inside and outside close poison.Evil poison accumulates and amasss in interior with the passing of time heat-transformation.So the rule of treatment is worked as based on heat-clearing and toxic substances removing.
Summary of the invention
The invention provides a kind of new Chinese medicine composition, the effect that said composition has heat clearing away, detoxifies, invigorates blood circulation is used for the treatment of various acute and chronic leukemias.
Another object of the present invention provides the preparation method of above-mentioned Chinese medicine composition.
The present invention is achieved by the following technical solutions:
The present invention is made by the following weight proportion raw material: Realgar 0.05-0.1 part, Indigo Naturalis 1.5-3 part, Radix Salviae Miltiorrhizae 9-15 part, Borneolum Syntheticum 0.15-0.3 part.
Preferred weight portion proportioning is: 0.08 part of Realgar, 2 parts of Indigo Naturaliss, 12 parts of Radix Salviae Miltiorrhizaes, 0.2 part of Borneolum Syntheticum.
The preparation method of Chinese medicine composition of the present invention is as follows:
Radix Salviae Miltiorrhizae water extraction or different concentration ethanol are extracted or water extract-alcohol precipitation, or water vapour distillation volatile oil medicinal residues water extraction or different concentration ethanol extraction or water extract-alcohol precipitation, also can further use the macroporous resin column purification, obtain Radix Angelicae Sinensis extract; Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum are mixed, add appropriate amount of auxiliary materials, be prepared into pharmaceutically acceptable solid orally ingestible, for example capsule, tablet, pill, drop pill etc.
Wherein, the preferred for preparation method of Radix Salviae Miltiorrhizae extract is:
Radix Salviae Miltiorrhizae adds 5 times of water gagings, decocts 2 hours, filters, filtering residue adds 4 times of water gagings, fries in shallow oil 1 hour, filters, filtering residue discards, and merges 2 times filtrate, and filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9-1.1, add ethanol and make medicinal liquid contain determining alcohol, leave standstill, filter 70%, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get Radix Salviae Miltiorrhizae extract.
Another preferred for preparation method of Radix Salviae Miltiorrhizae extract is:
Radix Salviae Miltiorrhizae adds 8 times of amount 70% ethanol extractions, and 2 times, each 1 hour, filter, filtering residue discards, and merges 2 times filtrate, reclaims ethanol, and being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get Radix Salviae Miltiorrhizae extract.
The preparation method of the preferred drop pill of Chinese medicine composition of the present invention is as follows:
With Macrogol 4000: polyethylene glycol 6000 adds the fine powder of Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum, mixing in 3: 1 ratio heating and melting, 60-80 ℃ of insulation splashes in the refrigerative simethicone, treats drop pill cooling back taking-up, drop is clean and wipe simethicone, promptly gets drop pill.
The preparation method of the preferred pill of Chinese medicine composition of the present invention is as follows:
Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, add proper honey, evenly mixed, the pill agent.
The preparation method of Chinese medicine composition preferred capsule of the present invention agent is as follows:
Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, add lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
The preparation method of another preferred capsule agent of Chinese medicine composition of the present invention is as follows:
Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, and drying incapsulates, and promptly gets capsule.
The preparation method of the preferred tablet of Chinese medicine composition of the present invention is as follows:
Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, add lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
The compatibility mechanism of pharmaceutical composition of the present invention is as follows:
The inventor thinks that the leukemic cause of disease is caused by " malicious heresy is gone into blood ", and this evil poison enters versatile thermal burn the moon behind the body, thereby again this malicious heresy is called burning hot heresy, also is referred to as fire-toxin, pyretic toxicity.The internal organs meridians of evil poison invasion human body under certain endogenous cause of ill condition, from outward appearance to inner essence, or poison is from interior and give birth to, inside and outside close poison.If a little less than the few power of evil poison amount then onset is slow, promptly arranged an incubation period, or the course of disease is longer.Evil poison accumulates and amasss in interior, with the passing of time heat-transformation, and consumption impairment of QI the moon, thereby the patient often shows as the syndrome that the cloudy consumption of gas is hindered in early days, clinical manifestation is a type of deficiency of both QI and YIN, is early stage or light-duty patient; Evil poison injures QI and blood in going into, and the two syndromes of losing of QI and blood occur, belongs to QIXUELIANGXU type; The poison heresy is further deeply invaded nutrient blood, attacks and annotates bone marrow, liver spleen and three warmers, makes imbalance of YIN and YANG, causes hemopoietic organ's dysfunction, and excessive noxious heat performances such as high fever, excessive thirst, epistaxis, a speckle appear in the remarkable outgrowth phenomenon of leukemogenesis cell.Syndromes such as unconsciousness and delirium then appear in pericardium if evil poison caves in, and as untimely treatment, it is cloudy depleted, beyond cure gas to occur, is difficult to treatment.Sb.'s illness took a turn for the worse on this many pro-amphitypy basis and form, also can be very strong because of evil virulence, and perhaps healthy energy extreme deficiency, evil poison is directly invaded nutrient blood, attacks notes bone marrow, and one falls ill promptly sees the excessive noxious heat phenomenon.Accumulate in the evil poison, internal damage by the excessive seven emotions in addition causes the heat immersion of burning, and blood is sticky, and depression and stagnation of QI causes stagnation of QI-blood eventually, and heat is burnt expectorant with fixed attention, and stagnation of QI mental disorder is condensed, then Jian Cheng mass in the abdomen, scrofula, grandular plague and see the enlargement of liver splenic lymph nodes.
According to the analysis of the above leukemic cause of disease course of disease, the treatment leukemia is worked as based on heat-clearing and toxic substances removing, and blood circulation promoting and blood stasis dispelling is auxilliary.In the drug composition, the mechanism of action of each medicine is as follows in the present invention:
Realgar: sulfide-based mineral Realgar family Realgar, the main realgar (As2S2) that contains.Suffering, temperature; Poisonous.Return liver, large intestine channel.The detoxifcation parasite killing, removing dampness and eliminating phlegm, preventing the attack (or recurrence) of malaria.Be used for the carbuncle furuncle, snake bite and insect sting, abdominal pain due to worm stagnation, infantile convulsion, malaria.
Indigo Naturalis: dried powder or agglomerate that the leaf of acanthaceous vegetable acanthaceous indigo Baphicacanthus cusia (Nees) Bremek., polygonaceae plant polygonum tinctorium ait. Polygonum tinctorium Ait. or cruciferae isatis Isatis indigoticaFort. or stem and leaf make through processing.Salty, cold.Return Liver Channel.Heat-clearing and toxic substances removing, removing heat from blood, arresting convulsion.Be used for maculae caused by violent heat pathogen, heat in blood is told nosebleed, chest pain hemoptysis, aphtha, mumps, sore throat, pediatric epilepsy scared.
Radix Salviae Miltiorrhizae: hardship is slightly cold.GUIXIN, Liver Channel.Stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, relieving restlessness clears away heart-fire.Be used for menoxenia, the amenorrhea dysmenorrhea, note of the ancient Chinese abdominal mass is gathered, breast ventral spine pain, pyretic arthralgia pain, skin infection swells and ache, dysphoria and insomnia; Hepatosplenomegaly, angina pectoris.
Borneolum Syntheticum: hot, bitter, be slightly cold.GUIXIN, spleen, lung meridian.The refreshment of having one's ideas straightened out, clearing away heat to alleviate pain.Be used for the calentura coma, convulsion is fainted, the apoplexy syncope due to accumulation of phlegm, stagnation of QI sudden syncope, attacked by pestiferous factors stupor, conjunctival congestion, aphtha, laryngopharynx swelling and pain, auditory meatus is suppurated.
Arsenic in China's T﹠B, is treated chronic myelocytic leukemia (CML) as past application detoxicating tablet of cow-bezoar (containing Realgar) and Realgar as antitumor drug.At the initial stage seventies, China takes the lead in obtaining higher clinical remission rate with arsenic agent treatment acute promyelocytic leukemia (APL).
The main component of Realgar is arsenic sulfide, discovers that wherein treating leukemic main compound is realgar (As2S2).Beijing Medical University's hematopathy institute report is treated acute promyelocytic leukemia 38 examples with Realgar, wherein 6 examples are to the drug-fast recurrence of multiple medicine patient, 2 examples are ATRA and the drug-fast recurrence of chemotherapeutics part patient, 30 examples are alleviated case fully for reaching after the ATRA treatment in addition, therapeutic scheme is 1000～1500mgd-1,2～3 weeks were a course of treatment, and the course of treatment is 2～3 weeks at interval, total 2 years half course of treatment.The result is after Realgar treatment 1～3 course of treatment, 8 examples partially or completely drug-fast patient alleviated fully, 30 examples are accepted the case of Realgar treatment in the complete catabasis, except that 3 examples withdraw from the treatment because of the side effect of other serious complication or Realgar, all the other 27 examples are continued complete remission all, all 35 routine patients to 1997 year survival always, actual survival rate was 100% in 3 years.Proved that as far back as people such as Zhou Aixiang in 1981 Realgar treatment leukemia is effective, complete remission rate 72%, part alleviates 28%, total effective rate 100%.Tang in 1998 uses the Chinese patent medicine LIUSHEN WAN, XIHUANG WAN, the zijin troche treatment acute and chronic leukemia that contain Realgar by monarch and obtains certain curative effect.The report utilization is treated acute and chronic leukemia by the pure Chinese medicinal preparation of Chinese prescriptions such as Realgar among the Yang Xins in 1999, and curative effect is better.This result has confirmed the effect that Realgar is cloned into gene level to the high efficiency and the special removing APL of APL treatment.(leukemic mechanism of arsenic agent treatment and clinical practice such as Realgar, the 19th the 2nd phase of volume of PLA's Acta Pharmaceutica Sinica)
Studies have shown that at present inducing apoptosis of tumour cell is a kind of clearer and more definite and important mechanism of Realgar antitumor action, different researchers adopts different malignant hematologic disease cells that the mechanism of its inducing apoptosis of tumour cell is furtherd investigate.In apoptotic molecular biology research process, it is found that several genes participates in apoptotic regulation and control, wherein the effect of bcl-2 gene receives much concern.The overexpression of bcl-2 not only can effectively stop the apoptosis that comprises that metabolite accumulation, free radical etc. bring out, and can suppress the apoptosis of many factors (as ray and oncogene) mediation.Some are discovered: the variation of bcl-2 gene family protein expression level can significantly change the impedance of tumor cell line to the induced by chemotherapeutic agents apoptosis.(research of Realgar induced apoptosis in leukemia cell lines, modern tumor medical science the 14th the 1st phase of volume of January in 2006)
In the present invention in the drug composition with Realgar as monarch drug, utilize the characteristic of its " treating the poisonous disease with poisonous drugs ", as the main medicine that produces therapeutic effect, Indigo Naturalis is got its heat clearing away, detoxifcation, removing heat from blood as ministerial drug effect is to cooperate and to implement the Chinese traditional treatment principle of heat-clearing and toxic substances removing, in addition, Radix Salviae Miltiorrhizae is invigorated blood circulation, and Borneolum Syntheticum is had one's ideas straightened out refreshment altogether for assistant makes, and four medicines share the effect of playing heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, pain relieving, removing heat from blood altogether.
The effect that Chinese medicine composition of the present invention has heat clearing away, detoxifies, invigorates blood circulation is used for the treatment of various acute and chronic leukemias, as acute leukemia, chronic myelocytic leukemia, polycythemia vera, acute promyelocytic leukemia etc.
Below, foregoing of the present invention is described in further detail by the specific embodiment:
Concrete embodiment
Embodiment 1:
Realgar 0.08kg, Indigo Naturalis 2kg, Radix Salviae Miltiorrhizae 12kg, Borneolum Syntheticum 0.2kg
Radix Salviae Miltiorrhizae adds 5 times of water gagings, decocts 2 hours, filters, filtering residue adds 4 times of water gagings, fries in shallow oil 1 hour, filters, filtering residue discards, and merges 2 times filtrate, and filtrate decompression is concentrated into 12L, add ethanol and make medicinal liquid contain determining alcohol, leave standstill, filter 70%, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get Radix Salviae Miltiorrhizae extract;
With 20kg Macrogol 4000 and 8kg polyethylene glycol 6000 heating and melting, add the fine powder of Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum, mixing, 60-80 ℃ of insulation splashes in the refrigerative simethicone, treats drop pill cooling back taking-up, drop is clean and wipe simethicone, promptly gets drop pill.
Embodiment 2:
Realgar 0.05kg, Indigo Naturalis 2kg, Radix Salviae Miltiorrhizae 12kg, Borneolum Syntheticum 0.2kg
Radix Salviae Miltiorrhizae adds 5 times of water gagings, decocts 2 hours, filters, filtering residue adds 4 times of water gagings, fries in shallow oil 1 hour, filters, filtering residue discards, and merges 2 times filtrate, and filtrate decompression is concentrated into 12L, add ethanol and make medicinal liquid contain determining alcohol, leave standstill, filter 70%, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get Radix Salviae Miltiorrhizae extract;
Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, add proper honey, evenly mixed, the pill agent.
Embodiment 3:
Realgar 0.1kg, Indigo Naturalis 2kg, Radix Salviae Miltiorrhizae 9kg, Borneolum Syntheticum 0.2kg
Radix Salviae Miltiorrhizae adds 8 times of amount 70% ethanol extractions, and 2 times, each 1 hour, filter, filtering residue discards, and merges 2 times filtrate, reclaims ethanol, and being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get Radix Salviae Miltiorrhizae extract;
Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, add the 10kg lactose, mixing is used 95% alcohol granulation, and drying incapsulates, and promptly gets capsule.
Embodiment 4:
Realgar 0.08kg, Indigo Naturalis 3kg, Radix Salviae Miltiorrhizae 15kg, Borneolum Syntheticum 0.3kg
Radix Salviae Miltiorrhizae adds 5 times of water gagings, decocts 2 hours, filters, filtering residue adds 4 times of water gagings, fries in shallow oil 1 hour, filters, filtering residue discards, and merges 2 times filtrate, and filtrate decompression is concentrated into 15L, add ethanol and make medicinal liquid contain determining alcohol, leave standstill, filter 70%, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get Radix Salviae Miltiorrhizae extract;
Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, and drying incapsulates, and promptly gets capsule.
Embodiment 5:
Realgar 0.08kg, Indigo Naturalis 1.5kg, Radix Salviae Miltiorrhizae 12kg, Borneolum Syntheticum 0.15kg
Radix Salviae Miltiorrhizae adds 8 times of amount 70% ethanol extractions, and 2 times, each 1 hour, filter, filtering residue discards, and merges 2 times filtrate, reclaims ethanol, and being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get Radix Salviae Miltiorrhizae extract;
Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, add the 6kg lactose, mixing is granulated, drying, and the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
Further set forth the beneficial effect of pharmaceutical composition of the present invention by following experiment:
Pharmaceutical composition of the present invention is to the experimentation of portable mouse lymphocyte leukemia (L7212) therapeutical effect
1 materials and methods
1.1 experiment material medicinal liquid of the present invention, propidium iodide, rat anti-mouse monoclonal antibody (anti-CD3-PE, anti-CD4-FITC, anti-CD8-FITC).615 inbred mouses, Mus 5-8 in age week, body weight 18-24g, male and female half and half.Flow cytometer.The L7212 leukemia cell line.
1.2 experimental technique press document (Chu Jianxin, Qi Shuling, Lei Jianling, etc. the foundation of portable mouse leukemia model (L7212) and biological characteristics [J] thereof. Chinese tumor magazine, 1981,3 (4): 287) method is duplicated L7212 leukemia model.Mice is divided into normal control group, normal administration group (Chinese medicine high dose), L7212 model group, L7212 Chinese medicine 1 group of (Chinese medicine high dose) and 2 groups in L7212 Chinese medicine (dosage in the Chinese medicine) at random.2 groups in normal administration group, 1 group in L7212 Chinese medicine and L7212 Chinese medicine give medicinal liquid of the present invention, and (high dose Chinese medicine is the medicinal liquid that contains crude drug 8g/ml, in dosage Chinese medicine be the medicinal liquid that contains crude drug 4g/ml) 0.3ml/ only irritates stomach, normal control group and L7212 model group are given the equal-volume normal saline.Each group every day 1 time, is total to administration 7d all in inoculation gastric infusion next day.
1.3 observation index (1) life span is calculated with formula (T-C)/C * 100%, increase in life span T is a treatment group The average survival time natural law, and C is a matched group The average survival time natural law.(2) peripheral blood leucocyte sum and differential counting, the differential counting of bone marrow nucleated cell smear, liver, spleen, thymus index.(3) mensuration of residual leukemic cell is pressed document (Zheng Dexian, Wu Kefu, Chu Jianxin. modern experimental hematology research method and technology [M]. Beijing: combined publication society of China Concord Medical Science University of Beijing Medical University, 1999,510) method adopts the biological implantation test to detect.(4) press cell generation cycle document (Jiang Bo, Zhang Yali, Zhou Dianyuan. molecular biology common experimental method [M]. Beijing: method People's Medical Officer Press 1996,118), detect with flow cytometer.T lymphocyte subset the group detect with flow cytometer.
1.4 the statistical procedures measurement data is so that (x ± S) expression adopts the t check.
2 results
Relatively see Table 1 2.1 respectively organize life span.The result shows in the 1st, the 2 batch of experiment that the L7212 Chinese drug-treated group all prolongs (p＜0.05 or 0.01) to some extent than L7212 model group life span, and life span difference does not have significance (p＞0.05) between 1,2 groups of groups of L7212 Chinese medicine.
Table 1 is respectively organized life span relatively (d, x ± S)
Compare * p＜0.05, * * p＜0.01 with the L7212 model group.Down together.
Relatively see Table 2 2.2 respectively organize peripheral blood leucocyte counting and classification.The result shows L7212 model group and the obviously rising on the 5th after inoculation of 1 group of mice peripheral blood leucocyte counting of L7212 Chinese medicine, but difference does not have significance (p＞0.05).Inoculation back the 8th day, as seen a large amount of leukaemias in two groups of mice peripheral blood films, and 1 group of leukaemia's percentage ratio of L7212 Chinese medicine is lower than L7212 model group (p＜0.01).
Table 2 is respectively organized relatively (x ± S) of peripheral blood leucocyte counting and leukaemia's percentage ratio
Relatively see Table 3 2.3 respectively organize bone marrow leukemia cells percentage ratio.A small amount of leukaemia has appearred in inoculation back the 5th day in the mouse bone marrow cells, but two groups of results close (p＞0.05).Inoculation back the 8th day, leukaemia's percentage ratio is starkly lower than the L7212 model group in 1 group of mouse bone marrow cells of L7212 Chinese medicine, but because the routine number of observation is few, does not take statistics.
Table 3 is respectively organized bone marrow leukemia cells percentage ratio relatively (%, x ± S)
2.4 respectively organized liver, spleen, thymus index relatively after L7212 model group and the L7212 Chinese medicine 1 winding kind the 5th day, the live mice (6) that kills and liver, the index and spleen index close (p＞0.05) of the dead mice of leukemia (4 batches, totally 44).Spleen, the thymus index close (p＞0.05) of normal administration group mice.
The residual leukemic cell measurement result compares the L7212 model group and 1,2 groups of mice life spans of L7212 Chinese medicine compare not statistically significant 2.5 respectively organize.
Relatively see Table 4 2.6 respectively organize the proliferation of bone marrow cells period profile.The result shows that normal matched group of 1 group of bone marrow cells in mice G2/G1 of L7212 Chinese medicine ratio and L7212 model group reduce.
Table 4 is respectively organized relatively (x ± S) of proliferation of bone marrow cells period profile
Compare △ P＜0.05 with the normal control group.Down together
2.7 respectively organize spleen, the t lymphocyte subset group relatively sees Table 5.L7212 group mouse spleen t lymphocyte subset group CD3+, CD4+, CD8+ percentage ratio are lower than normal group more, and CD4+/CD8+ ratio is lower than not administration group (normal control group, L7212 model group) more.
Table 5 is respectively organized relatively (x ± S) of spleen, t lymphocyte subset group
3 conclusions
This experiment shows that pharmaceutical composition of the present invention has better curative effect to leukemia, because of its life span that can prolong the L7212 leukemia mouse, reduces the ratio of leukaemia in its peripheral blood, so this side is objective effective to the treatment leukemia.
Claims (10)
1, a kind ofly is used for the treatment of leukemic Chinese medicine composition, it is characterized in that it is to be made by following bulk drugs: Realgar 0.05-0.1 part, Indigo Naturalis 1.5-3 part, Radix Salviae Miltiorrhizae 9-15 part, Borneolum Syntheticum 0.15-0.3 part.
According to the Chinese medicine composition of claim 1, it is characterized in that 2, it is to be made by following bulk drugs: 0.08 part of Realgar, 2 parts of Indigo Naturaliss, 12 parts of Radix Salviae Miltiorrhizaes, 0.2 part of Borneolum Syntheticum.
3, the preparation method of claim 1 or 2 described Chinese medicine compositions, it is characterized in that, this method is: Radix Salviae Miltiorrhizae water extraction or different concentration ethanol are extracted or water extract-alcohol precipitation, or water vapour distillation volatile oil medicinal residues water extraction or different concentration ethanol extraction or water extract-alcohol precipitation, also can further use the macroporous resin column purification, obtain Radix Salviae Miltiorrhizae extract; Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum are mixed, add appropriate amount of auxiliary materials, be prepared into capsule, tablet, pill, drop pill.
4, the preparation method of Chinese medicine composition according to claim 3, it is characterized in that, the preparation method of Radix Salviae Miltiorrhizae extract is: Radix Salviae Miltiorrhizae adds 5 times of water gagings, decocted 2 hours, and filtered, filtering residue adds 4 times of water gagings, fried in shallow oil 1 hour, filter, filtering residue discards, and merges 2 times filtrate, filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9-1.1, add ethanol and make medicinal liquid contain determining alcohol, leave standstill, filter 70%, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), drying under reduced pressure (60 ℃ ,-0.08Mpa), promptly get Radix Salviae Miltiorrhizae extract.
5, the preparation method of Chinese medicine composition according to claim 3 is characterized in that, the preparation method of Radix Salviae Miltiorrhizae extract is: Radix Salviae Miltiorrhizae adds 8 times of amount 70% ethanol extractions, 2 times, each 1 hour, filter, filtering residue discards, merge 2 times filtrate, reclaim ethanol, being concentrated into relative density is the thick paste of 1.30-1.35 (50 ℃), (60 ℃ of drying under reduced pressure,-0.08Mpa), promptly get Radix Salviae Miltiorrhizae extract.
6, the preparation method of Chinese medicine composition according to claim 3, it is characterized in that, the preparation method of drop pill is: with Macrogol 4000: polyethylene glycol 6000 was in 3: 1 ratio heating and melting, the fine powder that adds Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum, mixing, 60-80 ℃ of insulation, splash in the refrigerative simethicone, treat drop pill cooling back taking-up, drop is clean and wipe simethicone, promptly gets drop pill.
7, the preparation method of Chinese medicine composition according to claim 3 is characterized in that, the preparation method of pill is: Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, add proper honey, and evenly mixed, the pill agent.
8, the preparation method of Chinese medicine composition according to claim 3 is characterized in that, the preparation method of capsule is: Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, add lactose, mixing is used 95% alcohol granulation, drying incapsulates, and promptly gets capsule.
9, the preparation method of Chinese medicine composition according to claim 3 is characterized in that, the preparation method of capsule is: Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, and drying incapsulates, and promptly gets capsule.
10, the preparation method of Chinese medicine composition according to claim 3, it is characterized in that the preparation method of tablet is: Radix Salviae Miltiorrhizae extract, Realgar, Indigo Naturalis, Borneolum Syntheticum powder are broken into fine powder, add lactose, mixing, granulate, drying, the adding magnesium stearate is an amount of, mixing, tabletting, coating promptly gets tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101132197A CN101590103B (en) | 2008-05-27 | 2008-05-27 | Traditional Chinese medicine combination for treating leukemia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101132197A CN101590103B (en) | 2008-05-27 | 2008-05-27 | Traditional Chinese medicine combination for treating leukemia and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101590103A true CN101590103A (en) | 2009-12-02 |
| CN101590103B CN101590103B (en) | 2012-07-18 |
Family
ID=41405103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101132197A Active CN101590103B (en) | 2008-05-27 | 2008-05-27 | Traditional Chinese medicine combination for treating leukemia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101590103B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362340A (en) * | 2015-12-17 | 2016-03-02 | 亿帆鑫富药业股份有限公司 | Medicine composition for treating leukemia and preparation method thereof |
| CN106728924A (en) * | 2017-03-01 | 2017-05-31 | 安徽天康(集团)股份有限公司 | It is a kind of to treat Chinese medicine composition of leukaemia and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1048873C (en) * | 1993-04-02 | 2000-02-02 | 包鸿廷 | Traditional herb medicine for treating leukaemia |
| CN1105567C (en) * | 1998-09-29 | 2003-04-16 | 王进平 | Medicine for treating leukemia and its preparing process |
-
2008
- 2008-05-27 CN CN2008101132197A patent/CN101590103B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362340A (en) * | 2015-12-17 | 2016-03-02 | 亿帆鑫富药业股份有限公司 | Medicine composition for treating leukemia and preparation method thereof |
| WO2017101236A1 (en) * | 2015-12-17 | 2017-06-22 | 亿帆鑫富药业股份有限公司 | Medicine composition for treating leukemia and preparation method therefor |
| AU2016370126B2 (en) * | 2015-12-17 | 2018-12-06 | Yi Fan Pharmaceutical Academy (Beijing) Co., Ltd. | Medicine composition for treating leukemia and preparation method therefor |
| CN106728924A (en) * | 2017-03-01 | 2017-05-31 | 安徽天康(集团)股份有限公司 | It is a kind of to treat Chinese medicine composition of leukaemia and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101590103B (en) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN1772262A (en) | Broad-spectrum cancer-treating Chinese medicine prepn and its prepn process | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN101590091B (en) | Traditional Chinese medicine combination for treating leukemia and preparation method thereof | |
| CN101590092B (en) | Traditional Chinese medicine combination for treating leukemia and preparation method thereof | |
| CN101590103B (en) | Traditional Chinese medicine combination for treating leukemia and preparation method thereof | |
| CN102579999B (en) | Medicine for treating carcinous fever and preparation method thereof | |
| CN1709302A (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN102772611A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN101590193B (en) | Traditional Chinese medicine combination for treating leukemia and preparation method thereof | |
| CN101474388B (en) | Improved prescription of Xianchan tablet medicament and preparation method thereof | |
| CN101590192B (en) | Traditional Chinese medicine combination for treating leukemia and preparation method thereof | |
| CN1895593A (en) | Medicine for treating acne and its preparation | |
| CN101164558B (en) | Clot-dispersing pain-relieving medicinal composition and preparation method and application thereof | |
| CN104984262A (en) | Chinese herb preparation treating ischemia apoplexy and preparing method of Chinese herb preparation | |
| CN104706729A (en) | Traditional Chinese medicine extract with antitumor effect as well as extraction method and application thereof | |
| CN103919819A (en) | Poria cocos natural composition and anti-cancer vomit-preventing application thereof | |
| CN108635560A (en) | A kind of Chinese medicine and preparation method thereof for treating lymthoma | |
| CN1289104C (en) | Anticancer medicine and its preparation | |
| CN114949022B (en) | Traditional Chinese medicine composition for treating tumors | |
| CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
| CN1709298A (en) | Chinese medicine formulation for treating chronic prostatitis and its preparing method | |
| CN1422641A (en) | Medicine for treating cancerous thoracoascites and preparation method | |
| CN101628044A (en) | Medicine for treating esophagus cancer and preparation method thereof | |
| CN1136900C (en) | Medicine for treating pulmonary tuberculosis and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170623 Address after: 519000, Guangdong, Zhuhai province Hengqin North Island Road No. 2522, Guangdong and Macao cooperation in traditional Chinese medicine science and Technology Industrial Park Business Service Center -19 (centralized office area) Patentee after: INCREASE (HENGQIN) PHARMACEUTICAL RESEARCH INSTITUTE CO.,LTD. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. |